PTHS
AMEX · Biotechnology
Pelthos Therapeutics Inc
$8.99
-0.40 (-4.26%)
Financial Highlights (FY 2026)
Revenue
31.37M
Net Income
-80,901,337
Gross Margin
76.2%
Profit Margin
-257.9%
Rev Growth
—
D/E Ratio
0.81
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 76.2% | 34.6% | 34.6% | 34.6% |
| Operating Margin | -194.8% | 15.6% | 18.3% | 16.9% |
| Profit Margin | -257.9% | 13.7% | 13.1% | 13.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 31.37M | 12.22M | 12.16M | 13.52M |
| Gross Profit | 23.92M | 4.22M | 4.20M | 4.67M |
| Operating Income | -61,097,315 | 1.91M | 2.23M | 2.28M |
| Net Income | -80,901,337 | 1.67M | 1.59M | 1.78M |
| Gross Margin | 76.2% | 34.6% | 34.6% | 34.6% |
| Operating Margin | -194.8% | 15.6% | 18.3% | 16.9% |
| Profit Margin | -257.9% | 13.7% | 13.1% | 13.2% |
| Rev Growth | — | +12.4% | +20.7% | +15.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 7.06M | 35.24M | 30.53M | 34.79M |
| Total Equity | 8.73M | 56.05M | 48.64M | 50.50M |
| D/E Ratio | 0.81 | 0.63 | 0.63 | 0.69 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -58,191,549 | 2.79M | 3.00M | 3.51M |
| Free Cash Flow | — | 1.30M | 1.27M | 1.44M |